Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1999-06-25
2003-11-11
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007100, C435S007210, C435S007800, C435S007930, C435S810000, C436S501000, C436S536000, C436S537000, C436S172000, C436S517000, C436S545000, C536S024100, C536S024300, C536S023100, C536S023740, C536S023740
Reexamination Certificate
active
06645733
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to fluorescent intensity based methods for assaying binding between ligands and receptors, particularly ligands and receptors comprising amino acids and/or amino acid analogs.
BACKGROUND OF THE INVENTION
A detection method typically employs at least one analytical reagent that binds to a specific target macromolecular species and produces a detectable signal. These analytical reagents typically have two components: (1) a probe macromolecule, for example, an antibody or oligonucleotide, that can bind a target macromolecule with a high degree of specificity and affinity, and (2) a detectable label, such as a radioisotope or covalently-linked fluorescent dye molecule. In general, the binding properties of the probe macromolecule define the specificity of the detection method, and the detectability of the associated label determines the sensitivity of the detection method. The sensitivity of detection is in turn related to both the type of label employed and the quality and type of equipment available to detect it.
For example, radioimmunoassays have been among the most sensitive and specific analytical methods used for detecting and quantitating biological macromolecules. Radioimmunoassay techniques have been used to detect and measure minute quantities of specific analytes, such as polypeptides, drugs, steroid hormones, polynucleotides, metabolites, and tumor markers, in biological samples. Radioimmunoassay methods employ immunoglobulins labeled with one or more radioisotopes as the analytical reagent. Radiation (alpha, beta or gamma) produced by decay of the attached radioisotope label serves as the signal which can be detected and quantitated by various radiometric methods.
Radioisotope based assays used to measure peptide-protein, ligand-receptor or drug-receptor interactions have typically required one component (usually the peptide, ligand or drug) to be radioactively labeled with either
125
I,
35
S,
32
P or
3
H for detection and quantitation. Radioactive labeling is labor-intensive, time-consuming, a health and environmental hazard during synthesis, purification, storage, usage and disposal steps, and is relatively expensive. Radioligands or radioactively labeled peptides are most commonly labeled with
125
I, which emits mainly &ggr; radiation and some &bgr; radiation, and has a half-life of sixty days.
125
I is considered more dangerous than the other above-mentioned radioisotopes, due to its high volatility and the fact that it concentrates in the thyroid, thereby requiring more precautions and expense during its handling.
Conventionally, it has been necessary to separate interacting complexes from unbound radioactive probes either by filtration and extensive washing steps or by native polyacrylamide gel electrophoresis, followed by gel drying. Low affinity binding interactions may dissociate during extensive washing steps or migration through a gel, and thus not be detected. Dried gels are analyzed by autoradiography or phosphoimaging, which is very time-consuming, especially when
35
S or
3
H isotopes are used. Filtered
125
I-bound complexes are analyzed by scintillation counting in special &ggr; radiation scintillation counters.
Moreover, the sensitivity of traditional detection methods, such as radioimmunoassays, can be too low to detect particularly small or dilute samples.
Thus, a need has existed in the art for a simple, highly sensitive, effective and rapid method for analyzing interaction between ligands and receptors, particularly ligands and receptors comprising amino acids and/or amino acid analogs.
All references cited herein are incorporated herein by reference in their entireties.
SUMMARY OF THE INVENTION
The invention provides a method for assaying binding between at least one target and at least one probe, said method comprising:
providing at least one target comprising a peptide sequence or a peptide analog sequence;
providing at least one probe comprising an amino acid or a second amino acid analog, and at least one fluorophore;
providing a test medium comprising said at least one target and said at least one probe;
irradiating said test medium with radiation effective to cause said at least one fluorophore to emit fluorescent light; and
detecting a quenching effect on fluorescence emitted by said at least one fluorophore resulting from said binding,
wherein said binding is specific, and wherein said method is conducted without separating complexes of said at least one target and said at least one probe from free target and free probe prior to said quenching effect detecting, and without providing a signal quenching agent to quench said emitted fluorescence.
REFERENCES:
patent: 4207075 (1980-06-01), Liburdy
patent: 4220450 (1980-09-01), Maggio
patent: 4235869 (1980-11-01), Schwarzberg
patent: 4743535 (1988-05-01), Carrico
patent: 4761382 (1988-08-01), Woodhead et al.
patent: 4963477 (1990-10-01), Tchen
patent: 5171695 (1992-12-01), Ekins
patent: 5187106 (1993-02-01), Fritzsche et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5332659 (1994-07-01), Kidwell
patent: 5334537 (1994-08-01), Lee et al.
patent: 5445935 (1995-08-01), Royer
patent: 5503980 (1996-04-01), Cantor
patent: 5516635 (1996-05-01), Ekins et al.
patent: 5538848 (1996-07-01), Livak et al.
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5594138 (1997-01-01), Dykstra et al.
patent: 5674698 (1997-10-01), Zarling et al.
patent: 5747247 (1998-05-01), Kowalczykowski et al.
patent: 5756292 (1998-05-01), Royer
patent: 5783384 (1998-07-01), Verdine
patent: 5814468 (1998-09-01), Siiman et al.
patent: 5846729 (1998-12-01), Wu et al.
patent: 6297059 (2001-10-01), Song et al.
patent: 0 232 967 (1987-08-01), None
patent: 0 512334 (1992-11-01), None
patent: 0 599337 (1994-06-01), None
patent: WO 87/07955 (1987-12-01), None
patent: 92 18650 (1992-10-01), None
patent: 93 24652 (1993-12-01), None
patent: 94 12665 (1994-06-01), None
patent: WO 94/14980 (1994-07-01), None
patent: 94 25477 (1994-11-01), None
patent: WO 95/15981 (1995-06-01), None
patent: 96 34983 (1996-11-01), None
patent: 97 12995 (1997-04-01), None
patent: WO 98/04923 (1998-02-01), None
patent: WO 98/26093 (1998-06-01), None
Shearer et al., “Heterogeneity of IgG Determined by Fluorescence” inBiochemical Fluorescence: Concepts,vol. 2, (Chen et al., Eds. 1976), pp. 811-843.
Kadonaga et al., “Isolation of cDNA Encoding Transcription Factor Sp1 and Functional Analysis of the DNA Binding Domain,” Cell, 51:1079-1090, Dec. 24, 1987.
Lansdorp, “Close Encounters of the PNA Kind,” 14 Nature Biotechnology 1653 (Dec. 1996).
Matthews et al., “Analytical Strategies for the Use of DNA Probes,” 169 Analytical Biochemistry 1 (1988).
Motulsky, “The GraphPad Guide to Analyzing Radioligand Binding Data,” pp. 1-19, 1995-96.
Perry-O'Keefe et al., “Peptide Nucleic Acid Pre-Gel Hybridization: An Alternative to Southern Hybridization,” 93 Proc. Natl. Acad. Sci. USA 14670 (Dec. 1996).
“PNA Oligomers as Hybridization Probes,” vol. 1, Issue 2 of PerSeptive Biosystems Magazine.
Rawls, “Optimistic About antisense,” 75(22) Chem. Eng. News 35, 39 (Jun. 2, 1997).
Smulevitch et al., “Enhancement of Strand Invasion by Oligonucleotides Through Manipulation of Backbone Charge,” 14 Nature Biotechnology 1700 (Dec. 1996) (disclosed in Landsdorp, “Close Encounters of the PNA Kind,” 14 Nature Biotechnology 1653 (Dec. 1996).
Sturm et al., “The ubiquitous octamer-binding protein Oct.-1 contains a POU domain with a homeo box subdomain,” Genes & Development, 2:1582-1599, 1988.
Tomac et al., “Ionic Effects on the Stability and Conformation of Peptide Nucleic Acid Complexes,” 118 J.Am.Chem.Soc. 5544 (1996).
Uhlmann et al., Chemical Reviews, vol. 90, No. 4, pp. 543-584. 1990.
Wilson et al., “The VP16 Accessory Protein HCF Is a Family of Polypeptides Processed from a Large Precursor Protein,” Cell, 74:115-125, Jul. 16, 1993.
Cardullo et al, “Detection of nucleic acid hydridization by nonradiative fluorescence resonance energy transfer,” 85(23) PNAS USA 8790 (1988).
Coghlan, “One-step DNA test in a tube,” New Scie
Daksis Jasmine I.
Erikson Glen H.
Caesar Rivise Bernstein Cohen & Pokotilow Ltd.
Cheu Changhwa J
Ingeneus Corporation
Le Long V.
LandOfFree
Fluorescent intensity method for assaying binding between... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorescent intensity method for assaying binding between..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorescent intensity method for assaying binding between... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3126268